Article

Diabetic retinopathy found in pre-diabetic patients

Diabetic retinopathy was found in nearly 8% of participants who were pre-diabetic and 12% of participants with type 2 diabetes in the Diabetes Prevention Program (DPP). The results were reported in a presentation at the American Diabetes Association's recent annual meeting.

Diabetic retinopathy was found in nearly 8% of participants who were pre-diabetic and 12% of participants with type 2 diabetes in the Diabetes Prevention Program (DPP). The results were reported in a presentation at the American Diabetes Association's recent annual meeting.

"These findings reinforce the recommendation that patients with newly diagnosed type 2 diabetes should be screened for retinopathy," said Emily Chew, MD, of the National Eye Institute, which funded the study. "We advise good control of blood glucose, blood pressure, and cholesterol as well as regular eye exams."

The program followed 3,234 people with impaired glucose tolerance. About 12% (302) of the DPP Outcome Study participants who had not developed diabetes during the study, and 588 of 876 participants who had developed diabetes, were selected to participate in the retinopathy study. To detect diabetic retinopathy, an evaluation of the fundus was performed.

Participants with pre-diabetes and retinopathy typically had a small number of microaneurysms in the eye, characteristic of early, mild retinopathy that is not yet linked to vision loss. Those who had developed diabetes in the previous 1 to 5 years had slightly more severe retinopathy, according to study outcomes. Higher average blood glucose levels and higher blood pressure were associated with the risk of developing retinopathy in the patients with new-onset diabetes, similar to previous findings in people with longstanding diabetes who develop retinopathy, the study authors said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.